Use of Teriparatide
Teriparatide should be reserved for postmenopausal women, men, and glucocorticoid-treated patients at very high risk of fracture—specifically those with severe or multiple vertebral fractures—and administered as 20 mcg subcutaneously daily for up to 2 years, followed immediately by antiresorptive therapy to maintain bone density gains. 1, 2
Patient Selection: Who Should Receive Teriparatide
Postmenopausal Women
Teriparatide is indicated for postmenopausal women at very high fracture risk, defined as 1:
- Severe or multiple vertebral fractures
- Patients who have failed or are intolerant to bisphosphonates or denosumab
- T-score ≤ -3.5 in younger patients (<65 years)
The 2019 Endocrine Society guidelines provide a strong recommendation (Grade 1|⊕⊕⊕O) for teriparatide or abaloparatide in this very high-risk population, emphasizing reduction of both vertebral and nonvertebral fractures 1. The 2023 American College of Physicians guidelines conditionally recommend teriparatide as second-line therapy for very high-risk patients 3.
Men with Osteoporosis
Teriparatide is FDA-approved for men with primary or hypogonadal osteoporosis at high fracture risk or those who have failed other therapies 2. The evidence base shows similar efficacy in men as in postmenopausal women for increasing BMD and reducing fracture risk 4.
Glucocorticoid-Induced Osteoporosis (GIOP)
For patients ≥40 years with GIOP at very high fracture risk, the 2022 ACR guidelines conditionally recommend teriparatide over antiresorptive agents 5. The 2017 ACR guidelines specifically note that teriparatide increased lumbar and hip BMD more than alendronate and decreased vertebral fractures at 36 months in GIOP patients 6, 7.
Very high risk in GIOP is defined as 5:
- History of osteoporotic fracture(s)
- FRAX 10-year risk for major osteoporotic fracture ≥30% or hip fracture ≥24.5%
- Very high-dose glucocorticoids (≥30 mg/day prednisone for >30 days or cumulative ≥25g/year)
Dosing and Administration
Standard Regimen
- Dose: 20 mcg subcutaneously once daily 2
- Site: Thigh or abdominal region 2
- Duration: Up to 2 years maximum in a patient's lifetime 4, 2
Pre-Treatment Assessment
Before initiating teriparatide, measure 4:
- Serum calcium
- Parathyroid hormone (PTH)
- 25-hydroxyvitamin D levels
- Alkaline phosphatase (to rule out Paget disease)
Supplementation
All patients should receive 2:
- Calcium: 1000-1200 mg/day
- Vitamin D: 600-800 IU/day (maintain serum 25(OH)D ≥20-30 ng/mL)
Initial Dosing Precautions
Administer the first doses under circumstances where the patient can sit or lie down, as transient orthostatic hypotension may occur 2. This typically resolves after the first few doses and rarely requires discontinuation 4.
Sequential Therapy: Critical for Maintaining Gains
This is a critical pitfall to avoid: When teriparatide is stopped, bone density declines rapidly within the following year 4.
Immediately follow teriparatide with antiresorptive therapy (strong recommendation, Grade 1|⊕⊕OO) 1:
- Bisphosphonates (oral or IV) are the preferred option
- Denosumab is an alternative
- No washout period or drug holiday is needed between stopping teriparatide and starting antiresorptive therapy 4
The 2020 AACE guidelines explicitly state there is "no apparent rationale for a washout period" between anabolic and antiresorptive treatment 4.
Contraindications and Precautions
Absolute Contraindications 4, 2
- Hypersensitivity to teriparatide or excipients
- Patients at increased risk of osteosarcoma:
- Paget disease of bone
- Open epiphyses (pediatric patients)
- Prior external beam or implant radiation therapy involving skeleton
- Unexplained elevation of skeletal alkaline phosphatase
- Bone metastases or history of skeletal malignancies
- Hereditary disorders predisposing to osteosarcoma
- Primary hyperparathyroidism or any untreated/unresolved secondary hyperparathyroidism
Relative Contraindications and Cautions
- Active or recent urolithiasis: Consider risk/benefit as teriparatide may exacerbate urolithiasis 2
- Hypercalcemic disorders: Avoid in patients with underlying hypercalcemia 2
- Worsening cutaneous calcification: Discontinue if this develops 2
- Pregnancy: Consider discontinuing when pregnancy is recognized 2
- Lactation: Breastfeeding not recommended 2
Monitoring During Treatment
Calcium Monitoring
- Measure serum calcium after 1 month of treatment 8
- If measured, draw blood at least 16 hours post-dose to avoid detecting transient hypercalcemia 4
- Transient hypercalcemia (4-6 hours post-dose) occurs in 11% of women and 6% of men but is usually mild and asymptomatic 2
- If hypercalcemia occurs: reduce dietary calcium supplements, consider reducing dosing frequency 8
Bone Turnover Markers
All bone formation markers (bone alkaline phosphatase, osteocalcin, procollagen type 1 N-terminal peptide) and resorption markers increase with teriparatide, reflecting its anabolic mechanism 4, 9.
Safety Profile
Common Adverse Events (>2% incidence) 2
- Arthralgia (10.1% vs 8.4% placebo)
- Pain (21.3% vs 20.5%)
- Nausea (8.5% vs 6.7%)
- Dizziness (8.0% vs 5.4%)
- Headache (7.5% vs 7.4%)
- Leg cramps (2.6% vs 1.3%)
Serious Adverse Events
- Osteosarcoma: The boxed warning regarding osteosarcoma (based on rat studies with very high doses) was removed in November 2023 2. Post-marketing surveillance studies found osteosarcoma incidence consistent with background rates in the general population 4, 2
- Orthostatic hypotension: Transient, occurs with initial doses, responds to recumbent posture 4
- Hypercalcemia: Usually mild, asymptomatic, and transient 4
Special Considerations
Prior Bisphosphonate Use
The anabolic effect of teriparatide appears "blunted" when used after bisphosphonates, with slower BMD gains 4. However, patients still benefit from fracture reduction related to improvements in bone geometry and microarchitecture 4.
After Denosumab
Do not switch from denosumab to teriparatide alone, as BMD decreases for 6-12 months after the switch 4. Teriparatide may be added to ongoing denosumab therapy if needed 4.
Combination Therapy
Concurrent use with bisphosphonates should be avoided, as it blunts the anabolic response 4, 8. The 2022 ACR guidelines conditionally recommend against using two different osteoporosis medications simultaneously 5.
Women of Childbearing Potential
For women meeting moderate-to-high fracture risk criteria who do not plan pregnancy and use effective contraception, oral bisphosphonates are preferred first-line. If bisphosphonates are inappropriate, teriparatide should be used 6, 7.
Cost and Access Considerations
Teriparatide is significantly more expensive than bisphosphonates 3, 8. The 2023 ACP guidelines note that bisphosphonates should be first-line treatment, with teriparatide reserved for very high-risk patients, partly due to cost considerations 3. Generic formulations should be prescribed when possible 3.
Duration of Treatment
The 2-year lifetime limit is based on 4, 2:
- Regulatory approval parameters
- Rat carcinogenicity studies (though the boxed warning was removed in 2023)
- Optimal anabolic window before diminishing returns
Use beyond 2 years should only be considered if the patient remains at or has returned to very high fracture risk 2.